THC–Tadalafil Drug Interaction
No direct, controlled pharmacokinetic or pharmacodynamic interaction study between tetrahydrocannabinol (THC) and tadalafil is included in tadalafil prescribing information. [1] Tadalafil exposure can increase with CYP3A4 inhibition, and THC can affect CYP450 activity, which creates a plausible pharmacokinetic interaction mechanism. [1], [2], [3]
Mechanism of Potential Interaction
Tadalafil is metabolized primarily by CYP3A4, and other CYP3A4 inhibitors are expected to increase tadalafil exposure. [1] THC is metabolized by CYP enzymes that include CYP3A4, and cannabinoids have demonstrated CYP enzyme inhibitory potential in preclinical and mechanistic studies. [2], [4] CYP3A4 overlap supports potential changes in tadalafil plasma concentrations when THC and other CYP3A4-active agents are co-administered. [2], [3]
Evidence Base and Clinical Relevance
Tadalafil labeling states that specific interactions with other agents have not been studied and that CYP3A4 inhibitors (examples listed in labeling) would likely increase tadalafil exposure. [1] Cannabinoid drug–drug interaction literature reports that cannabinoids can inhibit CYP-mediated metabolism, but the magnitude of CYP3A4-mediated in vivo interaction risk varies across studies. [2], [3] Systematic review evidence supports that drug interactions involving THC and cannabidiol occur through common CYP450 pathways shared with many conventional medications, including CYP3A4. [3]
Pharmacodynamic Overlap (Blood Pressure and Adverse Effects)
Tadalafil has known cardiovascular pharmacodynamic effects through PDE5 inhibition, and tadalafil exposure increases when CYP3A4 metabolism is inhibited. [1] Cannabis-related CYP modulation may therefore increase the likelihood of tadalafil-associated adverse effects that are exposure-related, including blood pressure–related events, based on the established exposure–effect relationship for tadalafil with CYP3A4 inhibitors. [1], [2]
Drug-Interaction Risk Factors
Risk of increased tadalafil exposure is higher with concurrent administration of CYP3A4 inhibitors, including agents specifically listed in tadalafil labeling. [1] THC products with stronger or more sustained CYP-modulatory effects increase the likelihood of clinically meaningful interaction through the shared CYP3A4 pathway. [2], [3] The interaction risk increases when additional CYP3A4 inhibitors are present alongside THC and tadalafil. [1], [2]
Practical Clinical Management
When co-use occurs, monitoring for tadalafil adverse effects associated with increased exposure is recommended, including symptoms consistent with hypotension (for example, dizziness) and common PDE5-inhibitor adverse effects (for example, headache or flushing). [1] Avoidance of additional strong CYP3A4 inhibitors with tadalafil remains recommended based on tadalafil labeling interaction precautions. [1] If co-use occurs, timing strategies that separate tadalafil dosing from THC do not remove the CYP3A4-mediated interaction risk because THC and cannabinoids may affect metabolic activity beyond a single moment of ingestion. [2], [3]
Common Pitfalls to Avoid
Assuming that “no known interaction” equals “no interaction risk” is a common error because tadalafil labeling notes that specific interactions have not been studied for many agents and still highlights likely exposure increases with CYP3A4 inhibitors. [1] Assuming that cannabinoids are clinically inert at drug-metabolizing enzymes is inaccurate because cannabinoid–CYP interaction evidence supports potential CYP inhibition. [2], [3] Ignoring co-administered CYP3A4 inhibitors increases the chance of unexpectedly high tadalafil exposure. [1]